Developer docs
API playgroundTry for free, no card

Search company profiles

REGiMMUNE

Full company profile

uuid0003to6

Namestring
REGiMMUNE
Legal namestring
REGiMMUNE Co, Ltd.
Websiteurl
regimmune.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

REGiMMUNE is a clinical-stage biotechnology company developing immune-regulatory therapeutics based on its proprietary reVax platform, which uses liposomal alpha-galactosylceramide (alpha-GalCer) formulations to pharmacologically induce regulatory T cells (Tregs) in an antigen-specific manner. Founded in 2006 and originating from technology exclusively licensed from Japan's RIKEN research institute, the company pursues a dual-modality strategy: enhancing Tregs to induce immune tolerance in transplantation (GvHD prevention), autoimmune disease, and allergy; and suppressing tumor-infiltrating Tregs to enable anti-tumor immunity in oncology. Its lead clinical asset, RGI-2001 (ToleroVax), is a liposomal formulation of KRN7000 that has completed a US Phase IIb trial for prevention of Graft-versus-Host Disease following allogeneic hematopoietic stem cell transplantation and has received FDA Orphan Drug Designation. The pipeline additionally includes antibody candidates RGI-Ab01 (Treg-targeting), RGI-Ab02 (checkpoint inhibitor), RGI-6004 (afucosylated anti-GARP/Latent-TGFb1), and AB08-H1 (anti-pan-MHC II for lymphoid malignancies and solid tumors).

The company is pre-commercial and generates revenue exclusively through licensing fees, upfront and milestone payments, and research funding from collaboration agreements rather than product sales. Distribution is achieved through pharmaceutical partnerships: a 2009 vaccine collaboration with Astellas Pharma, a 2015 JDRF/Pfizer collaboration for Type 1 Diabetes, and a 2023 license to San Fu Biotech for RGI-2001 development and commercialization across major Asian countries excluding Japan. The company has raised approximately $35-40M cumulatively across Series B through Series E equity rounds, plus a $12M grant from the Japan Science and Technology Agency in 2008, with its last disclosed funding round occurring in 2017. Operating geographies span Japan, Taiwan (where the company has shifted its operational headquarters), and the United States (US clinical operations), with preparations underway for a listing on Taiwan's Emerging Stock Market.

Short descriptiontext

REGiMMUNE is a clinical-stage biotechnology company developing immune-regulatory therapeutics that modulate regulatory T cells using its proprietary reVax liposomal alpha-GalCer platform, targeting GvHD prevention, autoimmune disease, allergy, and oncology indications through licensing and pharmaceutical partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, immune regulatory therapeutics, regulatory T cell modulation, graft-versus-host disease prevention, transplant tolerance therapy
Industry5 codes
PRIMARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Immuno-modulatory Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Sublicensing
TypeLicensing Royalties
Description

REGiMMUNE generates revenue through exclusive licensing agreements for its technology platforms and product candidates. The company has licensed rights to RIKEN's immune regulating technology and sublicenses its own products to partners like San Fu Biotech for major Asian countries.

regimmune.com
2Collaboration and Partnership Agreements
TypeLicensing Royalties
Description

Strategic collaborations with pharmaceutical companies including Astellas for vaccine technology and JDRF/Pfizer for Type 1 Diabetes research. These partnerships typically include upfront payments, research funding, milestone payments, and royalties.

regimmune.com
3Equity Financing
TypeLicensing Royalties
Description

The company has raised multiple equity financing rounds including Series B ($8M in 2008), Series C ($5M in 2012), Series D ($9.2M in 2014), and Series E ($6M in 2017) to fund clinical development.

regimmune.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1RGI-2001
Description

Lead product candidate - liposomal formulation of alpha-GalCer for GvHD treatment

regimmune.com
+5 more records
Core offering1 text field

REGiMMUNE is a clinical-stage biopharmaceutical company developing immune-regulatory therapeutics based on its proprietary reVax platform, which induces regulatory T cells (Tregs) to establish antigen-specific immune tolerance. Its lead candidate, RGI-2001 (ToleroVax), targets Graft-versus-Host Disease (GvHD) prevention in hematopoietic stem cell transplantation and has completed Phase IIb clinical trials with FDA Orphan Drug Designation. The pipeline also includes antibody therapeutics (RGI-Ab01, RGI-Ab02, RGI-6004, AB08-H1) addressing cancer, autoimmune disease, allergy, and type 1 diabetes indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase I/IIa study showed RGI-2001 was well-tolerated with no safety concerns up to highest dose; patients showed markedly increased Treg numbers within 1-3 weeks after HCT
+3 more records
Product overview1 text field

REGiMMUNE is a clinical-stage biopharmaceutical company developing immune regulatory therapeutics based on its proprietary reVax platform technology. The company's portfolio includes RGI-2001 (ToleroVax), a first-in-class Treg-inducing agent for GvHD prevention that has completed Phase IIb trials, alongside an antibody therapeutics pipeline featuring RGI-Ab01 (Treg silencing), RGI-Ab02 (checkpoint inhibitor), RGI-6004 (Treg depleting antibody), and AB08-H1 (anti-MHC II antibody for cancer). The reVax platform enables antigen-specific immune tolerance through Treg induction, supporting products across allergy, autoimmune diseases, transplantation, and oncology.

Product and service5 records
1RGI-2001 (ToleroVax)
CategoryCore clinical product (Treg-inducing therapeutic)
Description

Liposomal formulation of alpha-GalCer (KRN7000) that induces regulatory T cells to prevent Graft-versus-Host Disease following allogeneic hematopoietic stem cell transplantation. Lead clinical-stage product candidate with FDA Orphan Drug Designation granted October 2012.

2RGI-Ab01
CategoryPipeline antibody therapeutic (oncology)
Description

Potent, high affinity-binding antibody targeting a protein specifically expressed on Tregs in the tumor microenvironment. Designed for tumor microenvironment biology with greater potency, high tumor tissue penetration, attractive pharmacokinetics, and low toxicities without systemic Treg depletion. Currently in late discovery stage.

3RGI-Ab02
CategoryPipeline antibody therapeutic (oncology checkpoint inhibitor)
Description

Novel checkpoint inhibitor antibody binding to an inhibitory receptor expressed on CD8+ Effector T cells and NK cells. Designed for efficacy as monotherapy or in combination with anti-PD-1 therapies and other internal antibody products. Currently in early discovery.

4RGI-6004
CategoryPipeline antibody therapeutic (oncology, Treg depletion)
Description

Fully human afucosylated IgG1 antibody targeting the GARP/Latent-TGFb1 complex, designed to selectively deplete activated tumor-infiltrating Treg cells while leaving effector T cells intact. Demonstrated approximately 10 pM efficacy with minimal impact on platelets and hematological profile. Currently in preclinical/IND-enabling stage.

5AB08-H1
CategoryPipeline antibody therapeutic (oncology)
Description

Humanized IgG antibody targeting pan MHC II (HLA II) that induces cancer cell lysis through homotypic aggregation and lysosomal membrane permeabilization without ADCC or CDC mechanisms. Being developed for lymphoid malignancies (Hodgkin and Non-Hodgkin lymphomas) and solid cancers expressing MHC II.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1San Fu Biotech
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-07-06
Description

License agreement for development and commercialization of RGI-2001 in major Asian countries.REGiMMUNE signed underwriting contract with HuaNan Securities for Taiwan market entry.

regimmune.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2015-04-15
Description

Collaboration for Type 1 Diabetes Prevention and Treatment research promoting regulatory T-cells. Three-way partnership leveraging REGiMMUNE's Treg technology with JDRF funding and Pfizer expertise.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2009-07-22
Description

Collaboration to jointly research and develop a novel vaccine-platform technology. Partnership combines Astellas' screening and natural source-derived compound development capabilities with REGiMMUNE's immune liposome technology. Terms undisclosed.

4RIKEN
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2006-09-01
Description

Exclusive license agreement granting REGiMMUNE the right to market/sublicense pharmaceutical products based on RIKEN's immune regulating technology.

regimmune.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage gene and cell therapy company with engineered immune cell platforms including Treg engineering programs. Comparable as a clinical-stage Treg/cell therapy developer with overlapping immunology and oncology focus.

TypeDirect peer
Description

Develops engineered Treg cell therapies focused on organ transplantation and autoimmune diseases. Directly comparable in target indication (solid organ transplant tolerance) and Treg-modality approach to REGiMMUNE's RGI-2001.

TypeDirect peer
Description

Clinical-stage cell therapy company developing Treg-based therapies for autoimmune diseases. Comparable Treg-modality platform with overlapping autoimmune indications.

TypeBroad incumbent
Description

Global pharmaceutical company with active Treg-related research through the JDRF/Pfizer/REGiMMUNE Type 1 Diabetes collaboration and broad immunology pipeline. Relevant as a partner and large-cap incumbent in the immune-regulation space.

TypeEmerging player
Description

China-based biopharmaceutical company developing immuno-oncology biologics including antibodies targeting tumor microenvironment. Comparable on oncology antibody pipeline adjacent to REGiMMUNE's RGI-Ab01 and RGI-6004 programs.

TypeDirect peer
Description

Clinical-stage biotech developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. Directly comparable to REGiMMUNE on Treg-modulation approach and target indications (autoimmune, transplant tolerance).

7Bristol Myers Squibb
TypeBroad incumbent
Description

Large pharmaceutical company with established immunology franchise including transplant immunosuppression (Nulojix/belatacept) and active Treg-related research. Represents both a potential BD partner and competitive threat in transplant/autoimmune indications.

8Abata Therapeutics
TypeDirect peer
Description

Treg cell therapy company focused on autoimmune diseases, particularly progressive multiple sclerosis. Directly comparable on Treg-based approach and immune tolerance induction strategy.

TypeDirect peer
Description

Engineered Treg cell therapy company targeting autoimmune and inflammatory diseases. Directly comparable on Treg platform technology and autoimmune disease indications overlapping with REGiMMUNE's pipeline.

TypeBroad incumbent
Description

Japanese pharmaceutical company with active cell and gene therapy programs and an existing vaccine-platform collaboration with REGiMMUNE (announced 2009). Comparable as both a strategic partner and a broader incumbent in transplantation and immune-regulation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors29 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

REGiMMUNE

Immuno-modulatory Biopharmaceuticalsregimmune.com

REGiMMUNE is a clinical-stage biotechnology company developing immune-regulatory therapeutics that modulate regulatory T cells using its proprietary reVax liposomal alpha-GalCer platform, targeting GvHD prevention, autoimmune disease, allergy, and oncology indications through licensing and pharmaceutical partnerships.

What REGiMMUNE does

REGiMMUNE is a clinical-stage biotechnology company developing immune-regulatory therapeutics based on its proprietary reVax platform, which uses liposomal alpha-galactosylceramide (alpha-GalCer) formulations to pharmacologically induce regulatory T cells (Tregs) in an antigen-specific manner. Founded in 2006 and originating from technology exclusively licensed from Japan's RIKEN research institute, the company pursues a dual-modality strategy: enhancing Tregs to induce immune tolerance in transplantation (GvHD prevention), autoimmune disease, and allergy; and suppressing tumor-infiltrating Tregs to enable anti-tumor immunity in oncology. Its lead clinical asset, RGI-2001 (ToleroVax), is a liposomal formulation of KRN7000 that has completed a US Phase IIb trial for prevention of Graft-versus-Host Disease following allogeneic hematopoietic stem cell transplantation and has received FDA Orphan Drug Designation. The pipeline additionally includes antibody candidates RGI-Ab01 (Treg-targeting), RGI-Ab02 (checkpoint inhibitor), RGI-6004 (afucosylated anti-GARP/Latent-TGFb1), and AB08-H1 (anti-pan-MHC II for lymphoid malignancies and solid tumors).

The company is pre-commercial and generates revenue exclusively through licensing fees, upfront and milestone payments, and research funding from collaboration agreements rather than product sales. Distribution is achieved through pharmaceutical partnerships: a 2009 vaccine collaboration with Astellas Pharma, a 2015 JDRF/Pfizer collaboration for Type 1 Diabetes, and a 2023 license to San Fu Biotech for RGI-2001 development and commercialization across major Asian countries excluding Japan. The company has raised approximately $35-40M cumulatively across Series B through Series E equity rounds, plus a $12M grant from the Japan Science and Technology Agency in 2008, with its last disclosed funding round occurring in 2017. Operating geographies span Japan, Taiwan (where the company has shifted its operational headquarters), and the United States (US clinical operations), with preparations underway for a listing on Taiwan's Emerging Stock Market.

REGiMMUNE firmographics

Firmographics
Name
REGiMMUNE
Legal name
REGiMMUNE Co, Ltd.
Website
https://regimmune.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
REGiMMUNE is a clinical-stage biotechnology company developing immune-regulatory therapeutics that modulate regulatory T cells using its proprietary reVax liposomal alpha-GalCer platform, targeting GvHD prevention, autoimmune disease, allergy, and oncology indications through licensing and pharmaceutical partnerships.
Ownership category
akta.pro rank

REGiMMUNE industry classification

Industry
Product category
Immuno-modulatory Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceuticals
  • Immune regulatory therapeutics
  • Regulatory T cell modulation
  • Graft-versus-host disease prevention
  • Transplant tolerance therapy

Where REGiMMUNE is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

REGiMMUNE business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and Sublicensing: REGiMMUNE generates revenue through exclusive licensing agreements for its technology platforms and product candidates. The company has licensed rights to RIKEN's immune regulating technology and sublicenses its own products to partners like San Fu Biotech for major Asian countries.
  2. Collaboration and Partnership Agreements: Strategic collaborations with pharmaceutical companies including Astellas for vaccine technology and JDRF/Pfizer for Type 1 Diabetes research. These partnerships typically include upfront payments, research funding, milestone payments, and royalties.
  3. Equity Financing: The company has raised multiple equity financing rounds including Series B ($8M in 2008), Series C ($5M in 2012), Series D ($9.2M in 2014), and Series E ($6M in 2017) to fund clinical development.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

REGiMMUNE product offering

Product offering

Core offering

REGiMMUNE is a clinical-stage biopharmaceutical company developing immune-regulatory therapeutics based on its proprietary reVax platform, which induces regulatory T cells (Tregs) to establish antigen-specific immune tolerance. Its lead candidate, RGI-2001 (ToleroVax), targets Graft-versus-Host Disease (GvHD) prevention in hematopoietic stem cell transplantation and has completed Phase IIb clinical trials with FDA Orphan Drug Designation. The pipeline also includes antibody therapeutics (RGI-Ab01, RGI-Ab02, RGI-6004, AB08-H1) addressing cancer, autoimmune disease, allergy, and type 1 diabetes indications.

Product overview

REGiMMUNE is a clinical-stage biopharmaceutical company developing immune regulatory therapeutics based on its proprietary reVax platform technology. The company's portfolio includes RGI-2001 (ToleroVax), a first-in-class Treg-inducing agent for GvHD prevention that has completed Phase IIb trials, alongside an antibody therapeutics pipeline featuring RGI-Ab01 (Treg silencing), RGI-Ab02 (checkpoint inhibitor), RGI-6004 (Treg depleting antibody), and AB08-H1 (anti-MHC II antibody for cancer). The reVax platform enables antigen-specific immune tolerance through Treg induction, supporting products across allergy, autoimmune diseases, transplantation, and oncology.

Differentiator

Problem solved

Functional benefit

Brands

  • RGI-2001: Lead product candidate - liposomal formulation of alpha-GalCer for GvHD treatment
  • reVax
  • ToleroVax
  • RGI-1000 series
  • RGI-3100 series
  • RGI-4000 series

Products and services

  • RGI-2001 (ToleroVax) Liposomal formulation of alpha-GalCer (KRN7000) that induces regulatory T cells to prevent Graft-versus-Host Disease following allogeneic hematopoietic stem cell transplantation. Lead clinical-stage product candidate with FDA Orphan Drug Designation granted October 2012.
  • RGI-Ab01 Potent, high affinity-binding antibody targeting a protein specifically expressed on Tregs in the tumor microenvironment. Designed for tumor microenvironment biology with greater potency, high tumor tissue penetration, attractive pharmacokinetics, and low toxicities without systemic Treg depletion. Currently in late discovery stage.
  • RGI-Ab02 Novel checkpoint inhibitor antibody binding to an inhibitory receptor expressed on CD8+ Effector T cells and NK cells. Designed for efficacy as monotherapy or in combination with anti-PD-1 therapies and other internal antibody products. Currently in early discovery.
  • RGI-6004 Fully human afucosylated IgG1 antibody targeting the GARP/Latent-TGFb1 complex, designed to selectively deplete activated tumor-infiltrating Treg cells while leaving effector T cells intact. Demonstrated approximately 10 pM efficacy with minimal impact on platelets and hematological profile. Currently in preclinical/IND-enabling stage.
  • AB08-H1 Humanized IgG antibody targeting pan MHC II (HLA II) that induces cancer cell lysis through homotypic aggregation and lysosomal membrane permeabilization without ADCC or CDC mechanisms. Being developed for lymphoid malignancies (Hodgkin and Non-Hodgkin lymphomas) and solid cancers expressing MHC II.

Quantifiable outcome

  • Phase I/IIa study showed RGI-2001 was well-tolerated with no safety concerns up to highest dose; patients showed markedly increased Treg numbers within 1-3 weeks after HCT
  • +3 more outcomes

Companies that use REGiMMUNE

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

REGiMMUNE technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

REGiMMUNE partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and core.

  • San Fu BiotechmajorChannel Partner/ Reseller/ Distributor · 6 July 2023License agreement for development and commercialization of RGI-2001 in major Asian countries.REGiMMUNE signed underwriting contract with HuaNan Securities for Taiwan market entry.
  • JDRF and Pfizer Inc.majorStrategic or Co-development Partner · 15 April 2015Collaboration for Type 1 Diabetes Prevention and Treatment research promoting regulatory T-cells. Three-way partnership leveraging REGiMMUNE's Treg technology with JDRF funding and Pfizer expertise.
  • Astellas Pharma Inc.majorStrategic or Co-development Partner · 22 July 2009Collaboration to jointly research and develop a novel vaccine-platform technology. Partnership combines Astellas' screening and natural source-derived compound development capabilities with REGiMMUNE's immune liposome technology. Terms undisclosed.
  • RIKENcoreOEM/ Whitelabel/ Licensing Partner · 1 September 2006Exclusive license agreement granting REGiMMUNE the right to market/sublicense pharmaceutical products based on RIKEN's immune regulating technology.

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

REGiMMUNE competitors and assessment

Company assessment

Emerging players

  • Cellectis: Clinical-stage gene and cell therapy company with engineered immune cell platforms including Treg engineering programs. Comparable as a clinical-stage Treg/cell therapy developer with overlapping immunology and oncology focus.
  • Innovent Biologics: China-based biopharmaceutical company developing immuno-oncology biologics including antibodies targeting tumor microenvironment. Comparable on oncology antibody pipeline adjacent to REGiMMUNE's RGI-Ab01 and RGI-6004 programs.

Direct peers

  • Quell Therapeutics: Develops engineered Treg cell therapies focused on organ transplantation and autoimmune diseases. Directly comparable in target indication (solid organ transplant tolerance) and Treg-modality approach to REGiMMUNE's RGI-2001.
  • Kyverna Therapeutics: Clinical-stage cell therapy company developing Treg-based therapies for autoimmune diseases. Comparable Treg-modality platform with overlapping autoimmune indications.
  • Sonoma Biotherapeutics: Clinical-stage biotech developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. Directly comparable to REGiMMUNE on Treg-modulation approach and target indications (autoimmune, transplant tolerance).
  • Abata Therapeutics: Treg cell therapy company focused on autoimmune diseases, particularly progressive multiple sclerosis. Directly comparable on Treg-based approach and immune tolerance induction strategy.
  • GentiBio: Engineered Treg cell therapy company targeting autoimmune and inflammatory diseases. Directly comparable on Treg platform technology and autoimmune disease indications overlapping with REGiMMUNE's pipeline.

Broad incumbents

  • Pfizer: Global pharmaceutical company with active Treg-related research through the JDRF/Pfizer/REGiMMUNE Type 1 Diabetes collaboration and broad immunology pipeline. Relevant as a partner and large-cap incumbent in the immune-regulation space.
  • Bristol Myers Squibb: Large pharmaceutical company with established immunology franchise including transplant immunosuppression (Nulojix/belatacept) and active Treg-related research. Represents both a potential BD partner and competitive threat in transplant/autoimmune indications.
  • Astellas Pharma: Japanese pharmaceutical company with active cell and gene therapy programs and an existing vaccine-platform collaboration with REGiMMUNE (announced 2009). Comparable as both a strategic partner and a broader incumbent in transplantation and immune-regulation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

REGiMMUNE social profiles

Digital presence

REGiMMUNE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

REGiMMUNE leadership team

Management profile

Number of profiles

Profiles6 records

REGiMMUNE subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

REGiMMUNE funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors29 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

REGiMMUNE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about REGiMMUNE

What does REGiMMUNE do?

REGiMMUNE is a clinical-stage biopharmaceutical company developing immune-regulatory therapeutics based on its proprietary reVax platform, which induces regulatory T cells (Tregs) to establish antigen-specific immune tolerance. Its lead candidate, RGI-2001 (ToleroVax), targets Graft-versus-Host Disease (GvHD) prevention in hematopoietic stem cell transplantation and has completed Phase IIb clinical trials with FDA Orphan Drug Designation. The pipeline also includes antibody therapeutics (RGI-Ab01, RGI-Ab02, RGI-6004, AB08-H1) addressing cancer, autoimmune disease, allergy, and type 1 diabetes indications.

Is REGiMMUNE a public or private company?

REGiMMUNE is a private company. It is classified as venture growth investor backed and is currently operating.

When was REGiMMUNE founded?

REGiMMUNE was founded in 2006. It employs 1 to 10 people.

Where is REGiMMUNE based?

REGiMMUNE is headquartered in Tokyo, Japan, in the Asia region.

How does REGiMMUNE make money?

Three revenue lines are on record. Licensing and Sublicensing is the primary driver. The others are collaboration and Partnership Agreements and equity Financing.

Who are REGiMMUNE's main competitors?

Emerging players on record are Cellectis and Innovent Biologics. Direct peers are Quell Therapeutics, Kyverna Therapeutics, Sonoma Biotherapeutics, Abata Therapeutics and GentiBio. Broad incumbents are Pfizer, Bristol Myers Squibb and Astellas Pharma.

Does REGiMMUNE have an API?

No public API is recorded for REGiMMUNE.

What industry is REGiMMUNE in?

REGiMMUNE's product category is Immuno-modulatory Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAJ, Transplant & Immunosuppression Specialty Pharmaceuticals, with a secondary code of HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotechREGiMMUNE touts 'compelling' midstage data in stem call transplant patients, readies phase 3REGiMMUNE's RGI-2001 passed its phase 2 trial in 47 stem cell transplant patients, with no engraftment failures or serious adverse events. By day 180, 94% survived, 75% avoided aGVHD grades II-IV, and only 4% relapsed. The company is considering a phase 3 study.PR NewswireGlobal Regulatory T-Cell Therapies Market Report 2021-2035: In-depth Analysis of Completed, Ongoing and Planned Clinical Studies of Various Treg Cell TherapiesResearch and Markets has announced the publication of a market report analyzing the regulatory T-cell (Treg) therapies sector from 2021 to 2035, covering clinical trials, partnerships, funding, and market forecasts. The report identifies over 90 pharmaceutical companies and academic institutes developing approximately 95 Treg cell therapy product candidates, with capital investments of around USD 3 billion in the last five years. Key advanced-stage candidates include ALS001 (Coya Therapeutics), CLBS03 (Caladrius Biosciences), ILT-101 (ILTOO Pharma), NKTR-358 (Eli Lilly), and RGI-2001 (REGiMMUNE).GlobeNewswireREGiMMUNE Receives Grant Award From METIREGiMMUNE Corporation received a grant from Japan's METI under its Regional New Consortium Projects program. The one-time grant will fund development of its immune regulatory therapeutics for cedar allergy. The company's reVax technology is expected to address unmet needs in allergies and autoimmune diseases.